© Provided by Benzinga

Guardant Health Inc (NASDAQ: GH) and Exact Sciences Corp (NASDAQ: EXAS) shares are moving in different directions in Thursday’s after-hours session. Here’s a look at what’s going on.

What To Know: Guardant Health shares are plunging after the company announced results from its ECLIPSE study evaluating the performance of its blood test for detecting colorectal cancer. 

The test demonstrated 83% sensitivity in detecting individuals with colorectal cancer. Specificity was 90% in both individuals without advanced neoplasia and in those who had a negative colonoscopy result.

Exact Sciences owns Cologuard, a stool-based cancer test that would directly compete with Guardant Health’s blood test. Cologuard is FDA approved and identifies 92% of colorectal cancers, according to data from the company. 

Trending: Elon Musk Says Taking Legal Action Against Jet Tracker After Son X’s Car Intercepted By ‘Crazy Stalker’

Must Read: ‘He Can Continue To Do What The Last People Did At Twitter’ And Bend Rules, @ElonJet Creator Says Of Elon Musk

From Last Month: After Bill Gates Dumps Billions In Berkshire To Buy Microsoft, His Quiet Biotech Portfolio Has Made A New Trade

GH, EXAS Price Action: Guardant Health shares are down 40.6% in after hours at $24.50, while Exact Sciences shares are up 25.8% at $56.10, according to Benzinga Pro.

Photo: fernando zhiminaicela from Pixabay.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.